September 24, 2015

Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections

September 24, 2015

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

September 19, 2015

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

September 19, 2015

Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition

September 15, 2015

Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma’s Board of Directors

September 14, 2015

AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

September 14, 2015

Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)

September 11, 2015

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy

September 3, 2015

Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine

September 3, 2015

Kite Pharma to Participate in Upcoming Investor Conferences in September 2015

September 1, 2015

Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference

August 18, 2015

Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer

August 17, 2015

Kite Pharma Provides Update on KTE-C19 Clinical Trial

August 14, 2015

Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update

August 14, 2015

Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015

August 13, 2015

Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights

August 10, 2015

Kite Pharma Reports Second Quarter 2015 Financial Results

August 6, 2015

Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT

August 6, 2015

Kite Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast

August 5, 2015

Kite Pharma to Present at the Canaccord Genuity 35th Annual Growth Conference

August 4, 2015

Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer

July 1, 2015

Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs

June 22, 2015

Capricor Therapeutics, Inc. (Nasdaq: CAPR) to Ring The Nasdaq Stock Market Closing Bell

June 22, 2015

Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

June 19, 2015

Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET